{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:36:20Z","timestamp":1706747780474},"reference-count":50,"publisher":"Impact Journals, LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"DOI":"10.18632\/aging.205470","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T16:36:56Z","timestamp":1706719016000},"source":"Crossref","is-referenced-by-count":0,"title":["MAEL in human cancers and implications in prognostication and predicting benefit from immunotherapy over VEGFR\/mTOR inhibitors in clear cell renal cell carcinoma: a bioinformatic analysis"],"prefix":"10.18632","author":[{"given":"Jin","family":"Tao","sequence":"first","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinshan","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xu","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yafeng","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guodong","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiaoxia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guoqiang","family":"Wang","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leo","family":"Li","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusheng","family":"Han","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunwei","family":"Xu","sequence":"additional","affiliation":[{"name":"Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxian","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Clinical Trial, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Hangzhou, Zhejiang, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shangli","family":"Cai","sequence":"additional","affiliation":[{"name":"Burning Rock Biotech, Guangzhou, Guangdong, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuepei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"4661","DOI":"10.1242\/dev.124.22.4661","article-title":"maelstrom is required for an early step in the establishment of Drosophila oocyte polarity: posterior localization of grk mRNA.","volume":"12","author":"Ruohola-Baker","year":"1997","journal-title":"Development"},{"key":"2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/1745-6150-3-48","article-title":"Functional insight into Maelstrom in the germline piRNA pathway: a unique domain homologous to the DnaQ-H 3'-5' exonuclease, its lineage-specific expansion\/loss and evolutionarily active site switch.","volume":"3","author":"Trudeau","year":"2008","journal-title":"Biol Direct"},{"key":"3","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.celrep.2015.03.030","article-title":"Crystal Structure and Activity of the Endoribonuclease Domain of the piRNA Pathway Factor Maelstrom.","volume":"1","author":"Nureki","year":"2015","journal-title":"Cell Rep"},{"key":"4","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1261\/rna.049437.114","article-title":"Metazoan Maelstrom is an RNA-binding protein that has evolved from an ancient nuclease active in protists.","volume":"2","author":"Pillai","year":"2015","journal-title":"RNA"},{"key":"5","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1007\/s11033-009-9741-x","article-title":"Identification of a novel human cancer\/testis gene MAEL that is regulated by DNA methylation.","volume":"3","author":"Zhang","year":"2010","journal-title":"Mol Biol Rep"},{"key":"6","doi-asserted-by":"publisher","first-page":"5026","DOI":"10.18632\/oncotarget.13756","article-title":"Mael is essential for cancer cell survival and tumorigenesis through protection of genetic integrity.","volume":"8","author":"Shin","year":"2017","journal-title":"Oncotarget"},{"key":"7","doi-asserted-by":"publisher","first-page":"103914","DOI":"10.1016\/j.isci.2022.103914","article-title":"Maelstrom functions in the production of Siwi-piRISC capable of regulating transposons in Bombyx germ cells.","volume":"2","author":"Siomi","year":"2022","journal-title":"iScience"},{"key":"8","doi-asserted-by":"publisher","first-page":"342","DOI":"10.3892\/or.2013.2836","article-title":"Proteomic analysis reveals that MAEL, a component of nuage, interacts with stress granule proteins in cancer cells.","volume":"3","author":"Zhou","year":"2014","journal-title":"Oncol Rep"},{"key":"9","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bph.14790","article-title":"Stress granule: A promising target for cancer treatment.","volume":"17","author":"Cao","year":"2019","journal-title":"Br J Pharmacol"},{"key":"10","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1634\/stemcells.2006-0469","article-title":"Concise review: cancer\/testis antigens, stem cells, and cancer.","volume":"2","author":"Brodin","year":"2007","journal-title":"Stem Cells"},{"key":"11","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1158\/2326-6066.CIR-17-0415","article-title":"Maelstrom Directs Myeloid-Derived Suppressor Cells to Promote Esophageal Squamous Cell Carcinoma Progression via Activation of the Akt1\/RelA\/IL8 Signaling Pathway.","volume":"6","author":"Wang","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"12","doi-asserted-by":"publisher","first-page":"113331","DOI":"10.18632\/oncotarget.22970","article-title":"MAEL contributes to gastric cancer progression by promoting ILKAP degradation.","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"13","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1002\/ijc.30388","article-title":"MAEL expression links epithelial-mesenchymal transition and stem cell properties in colorectal cancer.","volume":"13","author":"Li","year":"2016","journal-title":"Int J Cancer"},{"key":"14","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1002\/hep.26677","article-title":"Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt\/GSK-3\u03b2\/Snail signaling.","volume":"5","author":"Guan","year":"2014","journal-title":"Hepatology"},{"key":"15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s13048-022-00992-4","article-title":"Maelstrom promotes tumor metastasis through regulation of FGFR4 and epithelial-mesenchymal transition in epithelial ovarian cancer.","volume":"1","author":"Yang","year":"2022","journal-title":"J Ovarian Res"},{"key":"16","doi-asserted-by":"publisher","first-page":"6281","DOI":"10.1038\/onc.2016.165","article-title":"Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B.","volume":"3","author":"Guan","year":"2016","journal-title":"Oncogene"},{"key":"17","doi-asserted-by":"publisher","first-page":"eabh2169","DOI":"10.1126\/sciadv.abh2169","article-title":"A single-cell type transcriptomics map of human tissues.","volume":"7","author":"von Feilitzen","year":"2021","journal-title":"Sci Adv"},{"key":"18","doi-asserted-by":"publisher","first-page":"eaal3321","DOI":"10.1126\/science.aal3321","article-title":"A subcellular map of the human proteome.","volume":"35","author":"Fagerberg","year":"2017","journal-title":"Science"},{"key":"19","doi-asserted-by":"publisher","first-page":"eaax9198","DOI":"10.1126\/science.aax9198","article-title":"A genome-wide transcriptomic analysis of protein-coding genes in human blood cells.","volume":"36","author":"von Feilitzen","year":"2019","journal-title":"Science"},{"key":"20","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.cell.2018.02.052","article-title":"An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics.","volume":"17","author":"Shriver","year":"2018","journal-title":"Cell"},{"key":"21","doi-asserted-by":"publisher","first-page":"W556","DOI":"10.1093\/nar\/gkz430","article-title":"GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis.","volume":"4","author":"Zhang","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"22","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1186\/s12864-015-1847-z","article-title":"MEXPRESS: visualizing expression, DNA methylation and clinical TCGA data.","volume":"1","author":"Van Criekinge","year":"2015","journal-title":"BMC Genomics"},{"key":"23","doi-asserted-by":"publisher","first-page":"W561","DOI":"10.1093\/nar\/gkz445","article-title":"MEXPRESS update 2019.","volume":"4","author":"De Meyer","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"24","doi-asserted-by":"publisher","first-page":"59336","DOI":"10.18632\/oncotarget.10659","article-title":"Establishment of a large panel of patient-derived preclinical models of human renal cell carcinoma.","volume":"7","author":"Massfelder","year":"2016","journal-title":"Oncotarget"},{"key":"25","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/ng.2323","article-title":"BAP1 loss defines a new class of renal cell carcinoma.","volume":"4","author":"Jain","year":"2012","journal-title":"Nat Genet"},{"key":"26","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1016\/j.immuni.2018.03.023","article-title":"The Immune Landscape of Cancer.","volume":"4","author":"Paull","year":"2018","journal-title":"Immunity"},{"key":"27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes.","volume":"57","author":"ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium","year":"2020","journal-title":"Nature"},{"key":"28","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/s41586-020-1970-0","article-title":"Genomic basis for RNA alterations in cancer.","volume":"57","author":"Li","year":"2020","journal-title":"Nature"},{"key":"29","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","article-title":"Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells.","volume":"4","author":"Haber","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"30","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-14-1128","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.","volume":"2","author":"Patard","year":"2015","journal-title":"Clin Cancer Res"},{"key":"31","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1056\/NEJMoa1510665","article-title":"Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.","volume":"37","author":"Gurney","year":"2015","journal-title":"N Engl J Med"},{"key":"32","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/nbt.3772","article-title":"Toil enables reproducible, open source, big biomedical data analyses.","volume":"3","author":"Craft","year":"2017","journal-title":"Nat Biotechnol"},{"key":"33","doi-asserted-by":"publisher","first-page":"D988","DOI":"10.1093\/nar\/gkab1049","article-title":"Ensembl 2022.","volume":"5","author":"Bignell","year":"2022","journal-title":"Nucleic Acids Res"},{"key":"34","doi-asserted-by":"publisher","first-page":"D419","DOI":"10.1093\/nar\/gky1038","article-title":"PANTHER version 14: more genomes, a new PANTHER GO-slim and improvements in enrichment analysis tools.","volume":"4","author":"Thomas","year":"2019","journal-title":"Nucleic Acids Res"},{"key":"35","doi-asserted-by":"publisher","first-page":"D325","DOI":"10.1093\/nar\/gkaa1113","article-title":"The Gene Ontology resource: enriching a GOld mine.","volume":"4","author":"Gene Ontology Consortium","year":"2021","journal-title":"Nucleic Acids Res"},{"key":"36","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.","volume":"10","author":"Mesirov","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"37","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1038\/s41467-020-15959-6","article-title":"PBRM1 loss defines a nonimmunogenic tumor phenotype associated with checkpoint inhibitor resistance in renal carcinoma.","volume":"1","author":"Martinez-Moczygemba","year":"2020","journal-title":"Nat Commun"},{"key":"38","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/s41581-020-0301-x","article-title":"Genomic profiling in renal cell carcinoma.","volume":"1","author":"Pal","year":"2020","journal-title":"Nat Rev Nephrol"},{"key":"39","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s12032-018-1231-3","article-title":"Comparison of axitinib and sunitinib as first-line therapies for metastatic renal cell carcinoma: a real-world multicenter analysis.","volume":"3","author":"Masumori","year":"2018","journal-title":"Med Oncol"},{"key":"40","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1016\/S1470-2045(15)00290-9","article-title":"Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial.","volume":"1","author":"Kremer","year":"2015","journal-title":"Lancet Oncol"},{"key":"41","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/S1470-2045(13)70465-0","article-title":"Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.","volume":"1","author":"Vogelzang","year":"2013","journal-title":"Lancet Oncol"},{"key":"42","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","article-title":"Clear cell renal cell carcinoma ontogeny and mechanisms of lethality.","volume":"1","author":"Rathmell","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"43","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41591-018-0053-3","article-title":"Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.","volume":"2","author":"Rathmell","year":"2018","journal-title":"Nat Med"},{"key":"44","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/s41591-020-0839-y","article-title":"Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma.","volume":"2","author":"Wind-Rotolo","year":"2020","journal-title":"Nat Med"},{"key":"45","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00262-023-03424-4","article-title":"BAP1-related signature predicts benefits from immunotherapy over VEGFR\/mTOR inhibitors in ccRCC: a retrospective analysis of JAVELIN Renal 101 and checkmate-009\/010\/025 trials.","volume":"7","author":"Shi","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"46","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2015.63.3651","article-title":"Biomarker: Predictive or Prognostic?","volume":"3","author":"Ballman","year":"2015","journal-title":"J Clin Oncol"},{"key":"47","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Comprehensive molecular characterization of clear cell renal cell carcinoma.","volume":"49","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"key":"48","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1038\/s41419-018-0504-2","article-title":"G3BP1 promotes tumor progression and metastasis through IL-6\/G3BP1\/STAT3 signaling axis in renal cell carcinomas.","volume":"9","author":"Geng","year":"2018","journal-title":"Cell Death Dis"},{"key":"49","doi-asserted-by":"publisher","first-page":"e004316","DOI":"10.1136\/jitc-2021-004316","article-title":"Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.","volume":"1","author":"Wind-Rotolo","year":"2022","journal-title":"J Immunother Cancer"},{"key":"50","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1016\/j.ccell.2020.10.011","article-title":"Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade.","volume":"3","author":"Lin","year":"2020","journal-title":"Cancer Cell"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205470","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T16:36:57Z","timestamp":1706719017000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.205470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,31]]},"references-count":50,"alternative-id":["205470"],"URL":"https:\/\/doi.org\/10.18632\/aging.205470","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,31]]}}}